GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice
Open accessThe DOI matches its Crossref record; 45 of the 47 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Glucagon-like peptide-1 receptor (GLP-1R) agonists are used to treat type 2 diabetes, and transient GLP-1 administration improved cardiac function in humans after acute myocardial infarction (MI) and percutaneous revascularization. However, the consequences of GLP-1R activation before ischemic myocardial injury remain unclear. RESEARCH DESIGN AND METHODS: We assessed the pathophysiology and outcome of coronary artery occlusion in normal and diabetic mice pretreated with the GLP-1R agonist liraglutide. RESULTS: Male C57BL/6 mice were treated twice daily for 7 days with liraglutide or saline followed by induction of MI. Survival was significantly higher in liraglutide-treated mice. Liraglutide reduced cardiac rupture (12 of 60 versus 46 of 60; P = 0.0001) and infarct size (21 ± 2% versus 29 ± 3%, P = 0.02) and improved cardiac output (12.4 ± 0.6 versus 9.7 ± 0.6 ml/min; P = 0.002). Liraglutide also modulated the expression and activity of cardioprotective genes in the mouse heart, including Akt, GSK3β, PPARβ-δ, Nrf-2, and HO-1. The effects of liraglutide on survival were independent of weight loss. Moreover, liraglutide conferred cardioprotection and survival advantages over metformin, despite equivalent glycemic control, in diabetic mice with experimental MI. The cardioprotective effects of liraglutide remained detectable 4 days after cessation of therapy and may be partly direct, because liraglutide increased cyclic AMP formation and reduced the extent of caspase-3 activation in cardiomyocytes in a GLP-1R–dependent manner in vitro. CONCLUSIONS: These findings demonstrate that GLP-1R activation engages prosurvival pathways in the normal and diabetic mouse heart, leading to improved outcomes and enhanced survival after MI in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“These agents exert their anti-atherosclerotic effects through various mechanisms, including by improving blood lipid profiles,444 preserving endothelial integrity and regulating endothelial function,445 as well as modulating inflammatory processes.70”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [445]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 4×
“Glucagon-like peptide-1 (GLP-1), a member of the proglucagon-derived peptide family (2), exerts favorable actions on cardiovascular function in both preclinical and clinical studies.”
BackgroundInfluentialSelf-citationRegulation of cardiac hypertrophy by intracellular signalling pathways
Heineke, J., & Molkentin, J. D. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1983 · Cited by 1,866 · cited 1×
“* ** ** Untreated Liraglutide EX(9-39) Liraglutide +EX(9-39) Forskolin 0 10 20 30 40 50 60”
Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · cited 3×
“The GLP-1 metabolite, GLP-1, also exerts cardioprotective actions when administered postischemia (3,16), further highlighting the complexity of different GLP-1–related peptides on the ischemic heart.”
BackgroundSelf-citationJuhaszova, M., Zorov, D. B., Kim, S.-H., Pepe, S., Fu, Q., Fishbein, K. W., Ziman, B. D., Wang, S., Ytrehus, K., Antos, C. L., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19906 · Cited by 1,026
Nikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901 · cited 3×
“A pilot study of GLP-1 administration for 72 h in human subjects with left ventricular (LV) dysfunction after myocardial injury and angioplasty demonstrated reduced hospital stay and improved global and regional LV wall motion scores, benefits that remained detectable even several weeks after hospital discharge (14).”
BackgroundResultGlucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851 · cited 2×
“* ** ** Untreated Liraglutide EX(9-39) Liraglutide +EX(9-39) Forskolin 0 10 20 30 40 50 60”
ResultSelf-citationHeymans, S., Luttun, A., Nuyens, D., Theilmeier, G., Creemers, E., Moons, L., Dyspersin, G. D., Cleutjens, J. P. M., Shipley, M., Angellilo, A., et al. (1999) · Nature Medicine · doi:10.1038/13459 · Cited by 794 · cited 2×
“* ** ** Untreated Liraglutide EX(9-39) Liraglutide +EX(9-39) Forskolin 0 10 20 30 40 50 60”
BackgroundSokos, G. G., Nikolaidis, L. A., Mankad, S., Elahi, D., & Shannon, R. P. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.08.211 · Cited by 656 · cited 2×
“Similarly, a 5-week course of GLP-1 infusion improved parameters of LV function, functional status, and quality of life in both diabetic and nondiabetic subjects with congestive heart failure (15).”
BackgroundGlucagon-like Peptide 1 Can Directly Protect the Heart Against Ischemia/Reperfusion Injury
Bose, A. K., Mocanu, M. M., Carr, R. D., Brand, C. L., & Yellon, D. M. (2005) · Diabetes · doi:10.2337/diabetes.54.1.146 · Cited by 638
Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis
Li, Y., Hansotia, T., Yusta, B., Ris, F., Halban, P. A., & Drucker, D. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209423200 · Cited by 589
Self-citation
Cited by
Items 501–592 of 592
Otterbeck, P. E., & Banerji, M. A. (2011) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.11.6 · Cited by 1
Inkretine: Gibt es kardiovaskuläre Effekte?
Gallwitz, B. (2010) · Herz · doi:10.1007/s00059-010-3333-3 · Cited by 1
“für die Gene Akt, GSK-3β, HO-1, „NF-E2-related factor-2“ und PPAR-β/δ [57].”
InfluentialZeraatian, S., Aghdam, R. M., & Hossein, A. S. (2015) · Cardiovascular Pharmacology Open Access · doi:10.4172/2329-6607.1000159 · Cited by 1
“Vasodilation and anti-inflammatory effects of native GLP-1 in the vascular endothelium and myocardium make GLP-1 one of the preferred treatments for type 2 diabetes mellitus [13-15].”
Background49 Cardiovascular Disease in the Bariatric Surgery Patient
Vest, A. R., & Young, J. B. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1637-5_49 · Cited by 1
DPP-4-Hemmer und GLP-1-Rezeptor-Agonisten: Kardiovaskuläre Effekte
Nauck, M. A., Aziz, M. S. A. E., & Meier, J. J. (2016) · Der Diabetologe · doi:10.1007/s11428-016-0083-8 · Cited by 1
“Auch auf andere potenzielle RisikofaktorenwurdenEinflüsse einerTherapie mit inkretinbasierten, den Glukosespiegel senkenden Medikamenten beschrieben, z. B. eine signifikante Reduktion des Bauchumfangs und des Apolipoprote- in-B-Gehaltes sowohl unter Liraglutidals auch unter Sitagliptingabe [28], eine deutlich Reduktio…”
BackgroundInfluentialIncretin-based therapies for the failing heart
Ussher, J. R., & Campbell, J. E. (2016) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000086 · Cited by 1
Bois, J. P., Gropler, R. J., & Peterson, L. R. (2018) · Current Cardiovascular Imaging Reports · doi:10.1007/s12410-018-9444-6 · Cited by 1
Polypharmakologie als ein neuer Ansatz zur Präzisionsmedizin in der Adipositas- und Diabetestherapie
Jall, S., Götz, A., Tschöp, M., & Müller, T. D. (2018) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/s-0038-1654054 · Cited by 2
Даниленко, Л. М., Pokrovsky, M. V., Dovgan, A. P., Kolesnichenko, P. D., Timokhina, A. S., & Kotelnikova, A. S. (2018) · Regional blood circulation and microcirculation · doi:10.24884/1682-6655-2018-17-1-90-96 · Cited by 1
Ovariektomize Sıçanlarda Liraglutid’in Kalp Fonksiyonları Üzerine Etkisi
TURAN, İ., Sağlam, C., Erdem, S., & ÖZAÇMAK, H. S. (2022) · Turkish Journal of Diabetes and Obesity · doi:10.25048/tudod.1074076 · Cited by 1
Peptides are cardioprotective drugs of the future. Glucagon-like peptide-1
Popov, S. V., Boshchenko, A. A., Маслов, Л. Н., Zhuravleva, O. A., Mukhomedzyanov, А. V., Сергеевна, С. А., Kan, A., Naryzhnaya, N. V., & Podoksenov, Y. K. (2025) · Сибирский журнал клинической и экспериментальной медицины · doi:10.29001/2073-8552-2025-40-3-11-18 · Cited by 1
Post-Genomic Analysis of Fatty Acid and Glucose Metabolism in Cardiovascular Disease
Marín-García, J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-404599-6.00016-0 · Cited by 1
Halter, C., Böhme, P., Ziegler, O., & Guerci, B. (2010) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(10)70085-7 · Cited by 2
Wu, L., Qin, Y., Zheng, X., Zhang, G., Zhou, Q., & Liu, L. (2025) · Research Square · doi:10.21203/rs.3.rs-5713487/v1 · Cited by 1
Giblett, J. P., Clarke, S. J., Dutka, D. P., & Hoole, S. P. (2019) · JACC: Journal of the American College of Cardiology · doi:10.25407/jacbts.c.4536203 · Cited by 1
GLP-1 receptor agonists and heart failure: insights from human genetics
Emanuelsson, F., & Benn, M. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf1058 · Cited by 1
Cellular aging in cardiovascular diseases
Oeseburg, H. (2010) · University of Groningen research database (University of Groningen / Centre for Information Technology)
Incretin-Based Treatment Strategy - GLP-1 Receptor Agonists (GLP-1R) or So-Called Incretin Mimetics
Perušičová, J., & Owe, K. (2011) · InTech eBooks · doi:10.5772/21873
GLP‐1 Biology, Signaling Mechanisms, Physiology, and Clinical Studies
Burcelin, R., Cabou, C., Magnan, C., & Gourdy, P. (2011) · Wiley eBooks · doi:10.1002/9780470910016.ch11
Studies on Incretins and Cardiovascular Function
Nathanson, D. (2010) · Figshare
Myokardiale Regeneration im Glukagon-like-peptide-1 Rezeptor knock out Mausmodell
Ebner, S. (2015) · Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.18266
Liraglutide: A Review of its Use in the Treatment of Diabetes Mellitus
Nicolucci, A., & Rossi, M. C. (2010) · Clinical Medicine Reviews in Vascular Health · doi:10.4137/cmrvh.s1652
Drucker, D. J. (2012) · Canadian Medical Association Journal · doi:10.1503/cmaj.112127
Self-citationTomoyasu, M., Kim‐Kaneyama, J., Kohashi, K., Shinmura, K., Nogi, Y., Terasaki, M., Nagashima, M., Miyazaki, A., & Hirano, T. (2014) · The Showa University Journal of Medical Sciences · doi:10.15369/sujms.26.191
Impact cardiovasculaire des incrétino-mimétiques chez le diabétique de type 2 : le point en 2015
Buysschaert, M., Amoussou-Guénou, D., Yanogo, D., & Djrolo, F. (2015) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(15)30036-5
Pharmacological cardioprotection in diabetes
Harding, I., Yellon, D. M., & Bell, R. M. (2015) · Diabetes Management · doi:10.2217/dmt.14.53
Mannucci, E. (2010) · Giornale italiano di cardiologia · doi:10.1714/565.6707
Papel da dipeptidil peptidase IV na fisiopatologia da insuficiência cardíaca
Salles, T. A. (2016) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2016.tde-11012016-145338
Intrapericardial delivery of Omega-3 Polyunsaturated fatty acids
Rolfes, C. (2012) · University of Minnesota Digital Conservancy (University of Minnesota)
Farah, L. X. S. (2015) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.5.2015.tde-05102015-114814
Arruda-Junior, D. F. (2015) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.5.2015.tde-09062015-163759
Widenmaier, S. B. (2010) · cIRcle (University of British Columbia) · doi:10.14288/1.0071070
“Similar findings were obtained in mice, although GLP-1 receptor-dependent actions were also involved (Ban et al., 2010; Ban et al., 2008; Noyan-Ashraf et al., 2009).”
ResultGLP 1 and Macrovascular Complications
Sleiman, D. (2011) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.s4-007 · Cited by 1
Paulo, S., & Girardi, C. (2015)
Gajos, G., Stefański, A., & Gumprecht, J. (2011) · PubMed
Lim, G. E. (2010) · TSpace (University of Toronto) · Cited by 1
The Role of the Glucagon-like Peptide-1 Receptor in Atherosclerosis
Panjwani, N. (2013) · TSpace (University of Toronto)
The Role of p21-activated Protein Kinase 1 in Metabolic Homeostasis
Chiang, Y. P. (2014) · TSpace (University of Toronto)
The Role of Transcription Factor 7-Like 2 in Hepatic Glucose Metabolism
Ip, W. (2014) · TSpace (University of Toronto)
Targets and Off-Targets of Kinase Inhibitors in Diabetes
Őrfi, Z. (2015) · MPG.PuRe (Max Planck Society)
Bois, J. P., & Gropler, R. J. (2017) · Journal of Nuclear Cardiology · doi:10.1007/s12350-017-1068-8
Inkretinbasierte Medikamente zur Diabetes- und Adipositastherapie
Götz, A., Jall, S., Tschöp, M., & Müller, T. D. (2017) · Der Diabetologe · doi:10.1007/s11428-017-0267-x · Cited by 1
“Außerdem konnte in Mäusen gezeigtwerden, dassGLP-1dieNeubildung von β-Zellen im endokrinen Pankreas fördert [1], das Risiko von Herz-Kreislauf-Erkrankungen verringert [37] und die Glukoneogenese in der Leber redu-”
BackgroundTARASOVА, A. P., Khavansky, A. V., Timokhina, A. S., Dovgan, A. P., Kostina, D. A., & SERNOV, L. N. (2017) · Кубанский научный медицинский вестник · doi:10.25207/1608-6228-2017-24-3-100-105
“217; 24 3) доксорубицин-опосредованное повреждение саркоплазматического ретикулума и митохондрий в аутофагических вакуолях [21].”
Clinical and basic studies of GLP-1 receptor agonists for the treatment of diabetes in China
Hong, T., Liu, J., & Wei, R. (2018) · Scientia Sinica Vitae · doi:10.1360/n052018-00030 · Cited by 1
Cardiovascular Outcomes with Liraglutide: An Update following LEADER
Ghosh, R. (2017) · Open Access Journal of Cardiology · doi:10.23880/oajc-16000101
Prevention of Microvascular Obstruction by Addressing Ischemia Reperfusion Injury—Part B
Pizarro, G., Fernández‐Jiménez, R., & Ibáñez, B. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812528-1.00016-6
Montvida, O. (2018) · Queensland University of Technology · doi:10.5204/thesis.eprints.122920
Zykov, V. A., Тучина, Т. П., Лебедев, Д. А., Крылова, И. Б., Bairamov, A. A., Babenko, A. Y., Galagudza, M. M., Кулешова, Э. В., & Grineva, E. N. (2019) · Translational Medicine · doi:10.18705/2311-4495-2019-6-4-22-34
Schroner, Z., & Uličiansky, V. (2019) · Vnitřní lékařství · doi:10.36290/vnl.2019.049
“Podobné účinky malo aj podanie liraglutidu [8].”
Efeito combinado da vildagliptina e do valsartan no tratamento da insuficiência cardíaca em ratos
Arruda-Junior, D. F. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2019.tde-08112019-163309
Taher, J. (2017) · TSpace (University of Toronto) · Cited by 1
GLP-1R Agonists & Cardiac Energy Metabolism in Type 2 Diabetes
Almutairi, M. G. (2019) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3-fhr3-cr50
Vastrad, B. M., & Vastrad, C. M. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.28.458005
Current literature in diabetes
(2009) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1037
Kanamarlapudi, V. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734616040.793572407
The entero-insular axis and metabolic syndrome
Sarkar, J., & Chakrabarti, P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85732-1.00047-5
Yu, L., & Qin, H. (2024) · Indian Journal of Pharmaceutical Sciences · doi:10.36468/pharmaceutical-sciences.1301
Lestari, Y. D., Santoso, D. I. S., Goenarjo, R. A., & Paramita, N. (2024) · Journal of Advance Research in Medical & Health Science · doi:10.61841/4r6k0m77
Nandave, M. (2024) · Springer eBooks · doi:10.1007/978-981-97-7568-2_8
Edwar, M., Kamar, M., Ashmawy, H. M. E., Ahmed, A. M., Kamel, A. A., Ragab, U., & Tawfik, O. F. (2024) · International Journal of Health Sciences · doi:10.21608/ijhegy.2024.345230.1052
Imran, F., Hussain, M., Mushtaq, U., Khaliq, I., Masood, S., & Zafar, Q. (2025) · Indus journal of bioscience research. · doi:10.70749/ijbr.v3i5.1533
Giglio, R. V., Gambino, C. M., Patti, A. M., Scazzone, C., Maggio, V., MURATORE, E., Agnello, L., RIZZO, M., & Ciaccio, M. (2025) · Biochimica Clinica · doi:10.23736/s0393-0564.25.00059-7
Sasidharan, S., & Lahareesh, B. L. (2025) · Global Journal of Health Sciences and Research · doi:10.25259/gjhsr_19_2025
Myat, A., Redwood, S. R., Arri, S. S., Gersh, B. J., Bhatt, D. L., & Marber, M. S. (2021) · Figshare · doi:10.6084/m9.figshare.13979203
Trombara, F., Cosentino, N., Bonomi, A., Ludergnani, M., Poggio, P., Gionti, L., Baviera, M., Colacioppo, P., Roncaglioni, M. C., Leoni, O., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26566868
Grau Bové, M. C. (2021) · Rovira & Virgili repository · Cited by 2
Effects of GLP-1 receptor agonists on pituitary and adrenal hormones
Heinla, K. (2023) · DSpace repository (University of Tartu) · Cited by 4
Hasse, M. (2024) · Qucosa (Saxon State and University Library Dresden)
Positron emission tomography imaging of disease activity in atherosclerosis
Virta, J. (2024) · UTUPub (University of Turku)
Drug Repurposing: Harnessing the Therapeutics from Antidiabetic Molecules
Bhatta, A., Mahale, P., Baral, H., Yuvaraj, D. K., & Kaundal, R. K. (2026) · Springer eBooks · doi:10.1007/978-981-95-4522-3_3
Reboldi, G. (2009) · Giornale italiano di cardiologia · doi:10.1714/582.6879
Thirugnanam, A. M., Chandrakanth, & Pruthvi (2026) · Cardiovascular revascularization medicine · doi:10.1016/j.carrev.2026.03.011
Dépôts de graisse ectopique : étude de leur développement et de leur modulation
Abdesselam, I. (2016) · theses.fr (ABES) · doi:10.70675/1f016024z175cz4b35z8034za3b418cfe9c3 · Cited by 1
Rôle des anses intestinales dans les effets métaboliques du gastric bypass : apport du modèle porcin
Marciniak, C. (2021) · theses.fr (ABES) · doi:10.70675/20ef750cz9657z4a87z8af5zc19b622f8793
Mechanism of GLP-1 Receptor Agonists in Weight Loss through Appetite Suppression
姚, 张. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1641386
Venkatesan, A., Martin, A., Katragadda, N., Tsui, S., Otten, M., Lee, R., & Sharma, G. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001330
Effect of emerging antiobesity and antidiabetic drugs on atherosclerosis
Armentaro, G., Severini, G., Pastura, C. A., Scarcelli, M. R., Cassano, V., & Sciacqua, A. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04438-3
“…and antiobesity drugs on atherosclerosis treatment significantly reduces atherosclerotic plaque development by decreasing proinflammatory pathways in aortic tissue and reducing macrophage infiltration (assessed by CD68 staining) and monocyte chemoattractant protein-1 (MCP-1) expression [56, 57].”
Fronc, K., Listos, P., Kasprzak, P., Berger, M., Słowik, T., Kotlinska, J. H., Poleszak, E., Baranowska‐Bosiacka, I., Emilia, L., Łupina, M., et al. (2026) · Brain Sciences · doi:10.3390/brainsci16070710 · Cited by 1
Pagel, P. S., Hang, D., Freed, J. K., & Crystal, G. J. (2026) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2026.07.032
Pagel, P. S., Hang, D., Freed, J. K., & Crystal, G. J. (2026) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2026.07.030
Hu, C., Zhao, W., Xiao, S., Shi, J., Liang, W., & Guo, R. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-026-06354-y
“Cardiomyocytes express GLP-1 receptors, and preclinical evidence indicates that GLP-1RA activation can limit ischemia-reperfusion injury and infarct size through receptor-dependent and -independent pro-survival signalling [16, 17].”
GLP-1RA pharmacokinetics and clinical effects: focus on cardiac, vascular, and glomerular structures
Barnaba, I., Massari, F., Ciccone, M. M., Caldarola, P., Campanella, C., Ricci, G., & Scicchitano, P. (2026) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2026.2714849
“Preclinical studies supported a possible cardioprotective effect of GLP-1R activation in ischemia-reperfusion models [43–47].”
Alshammari, A. N., Gadir, I. K. A., Abdulbaqi, A. A., Elamin, H. A., Abdalgadir, E. A., Eitah, H. E., Khormi, M. A., Hegazy, R. A., & Alshammery, S. (2026) · Journal of King Saud University - Science · doi:10.25259/jksus_1770_2025
Cardiovascular effects of incretin receptor agonists: beyond glycemic control
Ravić, M. P., Srejovic, I. M., Milosavljević, I., Novakovic, J. N., Jakovljević, V., Vučićević, K., Petrovic, D., & Muric, M. D. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2026-0184
心血管病に対するインクレチン製剤の心保護作用について(4.糖尿病における心血管病の特徴と対策,<特集>第76回日本循環器学会学術集会)
純一, 尾., & 野出孝一 (2012) · Journal of JCS Cardiologists · doi:10.1253/jjcsc.20.2_256
Metadata
- Authors
- Noyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A.-M., Zhou, Y.-Q., Riazi, A. M., Baggio, L. L., Henkelman, R. M., Husain, M., & Drucker, D. J.
- Affiliations
- Toronto General Hospital (CA)
- University of Toronto (CA)
- Mouse Imaging Centre, Department of Medical Biophysics, Hospital for Sick Children, Toronto, Ontario, Canada;
- Hospital for Sick Children (CA)
- Mount Sinai Hospital (CA)
- Corresponding author
- Drucker, Daniel J.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2009-01-16
- Volume
- 58
- Issue
- 4
- Pages
- 975-983
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC2661586
- OpenAlex
- W2150913805
- Cited by
- 575
- References
- 47
- Citations by year
- 2026: 17 · 2025: 25 · 2024: 26 · 2023: 20 · 2022: 21 · 2021: 28 · 2020: 25 · 2019: 25 · 2018: 32 · 2017: 36 · 2016: 33 · 2015: 49 · 2014: 41 · 2013: 47 · 2012: 53
- FWCI
- 35.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (80668)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Ischemia and Reperfusion
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- liraglutide, GLP-1 receptor agonists, myocardial infarction, cardioprotection, diabetic cardiomyopathy, cardiac rupture, infarct size, Akt/GSK-3β signaling, PPARδ, metformin, caspase-3, cyclic AMP
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Animals, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Disease Models, Animal, Heart, Cardiomegaly, Humans, Male, Mice, Inbred C57BL, Myocardial Infarction, Organ Size, Receptors, Glucagon, Mice, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.